• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C反应蛋白水平与卵巢癌后续风险之间的关联:对1852例卵巢癌患者的13个队列进行的荟萃分析

Association between C-reactive protein level and subsequent risk of ovarian cancer: A meta-analysis of 13 cohorts in 1,852 ovarian cancer patients.

作者信息

Wang Yan, Zhang Zhiming, Wang Jing, Zhang Xiaowei

机构信息

Department of Gynecology.

Department of Clinical Laboratory, Xi'an Central Hospital.

出版信息

Medicine (Baltimore). 2020 Jan;99(5):e18821. doi: 10.1097/MD.0000000000018821.

DOI:10.1097/MD.0000000000018821
PMID:32000385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7004735/
Abstract

BACKGROUND

Though studies have shown association between C-reactive protein (CRP) level and the risk of ovarian cancer (OC), there have been some inconsistencies. The current metaanalysis was conducted to study the relationship between CRP and OC.

PATIENTS AND METHODS

Three electronic databases of PubMed, Embase, and Cochrane Library were searched for prospective studies of OC from inception till May 2018. Relative risk (RR) was summarized using random-effects model, and the results of sensitivity, subgroup analyses, and publication biases were also calculated.

RESULTS

A total of 13 cohorts involving 1,852 OC patients were included for the final meta-analysis. The summary RRs indicated that high CRP was associated with an increased risk of all invasive OC (RR:1.36; 95% confidence interval [CI]:1.03-1.80; P = .032), while moderate CRP showed no significant impact on the risk of all invasive OC compared with low CRP (RR:1.17; 95% CI:0.97-1.41; P = .107). High (RR: 1.42; 95% CI: 0.85-2.37; P = .183) or moderate (RR: 1.29; 95% CI: 0.94-1.77; P = .119) CRP levels showed little or no effect on serous OC. Similarly, no significant differences for the comparisons of high versus low (RR: 1.82; 95% CI: 0.27-12.42; P = .540) or moderate versus low (RR: 0.72; 95% CI: 0.31-1.69; P = .455) CRP levels for the risk of mucinous OC were observed. Moreover, high (RR: 0.58; 95% CI: 0.13-2.54; P = .471) or moderate (RR: 0.81; 95% CI: 0.44-1.47; P = .484) CRP levels were not associated with the risk of endometrioid OC compared with low CRP levels.

CONCLUSION

High CRP levels were associated with increased risk of invasive OC. The risk of other OC types with CRP levels showed no association.

摘要

背景

尽管研究表明C反应蛋白(CRP)水平与卵巢癌(OC)风险之间存在关联,但仍存在一些不一致之处。本荟萃分析旨在研究CRP与OC之间的关系。

患者与方法

检索了PubMed、Embase和Cochrane图书馆这三个电子数据库,以查找从开始到2018年5月的OC前瞻性研究。使用随机效应模型汇总相对风险(RR),并计算敏感性、亚组分析和发表偏倚的结果。

结果

最终的荟萃分析共纳入了13个队列,涉及1852例OC患者。汇总RR表明,高CRP与所有侵袭性OC风险增加相关(RR:1.36;95%置信区间[CI]:1.03 - 1.80;P = 0.032),而与低CRP相比,中等CRP对所有侵袭性OC风险无显著影响(RR:1.17;95% CI:0.97 - 1.41;P = 0.107)。高(RR:1.42;95% CI:0.85 - 2.37;P = 0.183)或中等(RR:1.29;95% CI:0.94 - 1.77;P = 0.119)CRP水平对浆液性OC几乎没有或没有影响。同样,对于黏液性OC风险,高与低(RR:1.82;95% CI:0.27 - 12.42;P = 0.540)或中等与低(RR:0.72;95% CI:0.31 - 1.69;P = 0.455)CRP水平比较未观察到显著差异。此外,与低CRP水平相比,高(RR:0.58;95% CI:0.13 - 2.54;P = 0.471)或中等(RR:0.81;95% CI:0.44 - 1.47;P = 0.484)CRP水平与子宫内膜样OC风险无关。

结论

高CRP水平与侵袭性OC风险增加相关。CRP水平与其他OC类型的风险无关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/276780797eea/medi-99-e18821-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/952b539981fe/medi-99-e18821-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/cb136f26b526/medi-99-e18821-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/4e2f84aaf727/medi-99-e18821-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/bee1c0bd4247/medi-99-e18821-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/57823e595d76/medi-99-e18821-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/dd6f28cf9ca7/medi-99-e18821-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/276780797eea/medi-99-e18821-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/952b539981fe/medi-99-e18821-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/cb136f26b526/medi-99-e18821-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/4e2f84aaf727/medi-99-e18821-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/bee1c0bd4247/medi-99-e18821-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/57823e595d76/medi-99-e18821-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/dd6f28cf9ca7/medi-99-e18821-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b742/7004735/276780797eea/medi-99-e18821-g009.jpg

相似文献

1
Association between C-reactive protein level and subsequent risk of ovarian cancer: A meta-analysis of 13 cohorts in 1,852 ovarian cancer patients.C反应蛋白水平与卵巢癌后续风险之间的关联:对1852例卵巢癌患者的13个队列进行的荟萃分析
Medicine (Baltimore). 2020 Jan;99(5):e18821. doi: 10.1097/MD.0000000000018821.
2
Inflammatory Markers of CRP, IL6, TNFα, and Soluble TNFR2 and the Risk of Ovarian Cancer: A Meta-analysis of Prospective Studies.CRP、IL6、TNFα和可溶性TNFR2的炎症标志物与卵巢癌风险:一项前瞻性研究的荟萃分析
Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1231-9. doi: 10.1158/1055-9965.EPI-16-0120. Epub 2016 Jun 8.
3
Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis.C-反应蛋白在卵巢癌患者中的预后及临床病理意义:一项荟萃分析。
World J Surg Oncol. 2024 Jan 3;22(1):8. doi: 10.1186/s12957-023-03290-5.
4
Diabetes mellitus and risk of ovarian cancer. A systematic review and meta-analysis of 15 cohort studies.糖尿病与卵巢癌风险。对15项队列研究的系统评价和荟萃分析。
Diabetes Res Clin Pract. 2017 Aug;130:43-52. doi: 10.1016/j.diabres.2017.04.005. Epub 2017 Apr 13.
5
High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.高 C 反应蛋白水平与卵巢癌风险增加相关:卵巢癌队列联盟的研究结果。
Cancer Res. 2019 Oct 15;79(20):5442-5451. doi: 10.1158/0008-5472.CAN-19-1554. Epub 2019 Aug 28.
6
C-reactive protein and risk of ovarian cancer: A systematic review and meta-analysis.C反应蛋白与卵巢癌风险:一项系统评价与荟萃分析
Medicine (Baltimore). 2017 Aug;96(34):e7822. doi: 10.1097/MD.0000000000007822.
7
C-reactive protein concentrations and subsequent ovarian cancer risk.C反应蛋白浓度与后续卵巢癌风险
Obstet Gynecol. 2007 Apr;109(4):933-41. doi: 10.1097/01.AOG.0000257126.68803.03.
8
Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis.饮酒与上皮性卵巢癌风险。系统评价和荟萃分析。
Gynecol Oncol. 2012 Jun;125(3):758-63. doi: 10.1016/j.ygyno.2012.03.031. Epub 2012 Mar 23.
9
Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis.超敏C反应蛋白与全因、心血管及癌症死亡风险:一项荟萃分析。
Atherosclerosis. 2017 Apr;259:75-82. doi: 10.1016/j.atherosclerosis.2017.02.003. Epub 2017 Feb 9.
10
Hs-CRP in stroke: A meta-analysis.超敏C反应蛋白与中风:一项荟萃分析。
Clin Chim Acta. 2016 Jan 30;453:21-7. doi: 10.1016/j.cca.2015.11.027. Epub 2015 Nov 26.

引用本文的文献

1
Association of urinary arsenic concentrations with inflammation: overall and by folate intake, body mass index, and gender.尿砷浓度与炎症的关联:总体情况以及按叶酸摄入量、体重指数和性别分析
Int J Hyg Environ Health. 2025 Jun;267:114585. doi: 10.1016/j.ijheh.2025.114585. Epub 2025 May 28.
2
Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression.卵巢癌腹水蛋白质组学图谱反映疾病进展过程中的代谢变化。
Biochem Biophys Rep. 2024 Jun 13;39:101755. doi: 10.1016/j.bbrep.2024.101755. eCollection 2024 Sep.
3
Associations between common contraceptive use and circulating inflammatory biomarkers.

本文引用的文献

1
High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.高 C 反应蛋白水平与卵巢癌风险增加相关:卵巢癌队列联盟的研究结果。
Cancer Res. 2019 Oct 15;79(20):5442-5451. doi: 10.1158/0008-5472.CAN-19-1554. Epub 2019 Aug 28.
2
IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis.白细胞介素-6与卵巢癌:促进转移的炎性细胞因子
Cancer Manag Res. 2018 Dec 5;10:6685-6693. doi: 10.2147/CMAR.S179189. eCollection 2018.
3
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
常见避孕方法的使用与循环炎症生物标志物之间的关联。
Am J Epidemiol. 2025 Jan 8;194(1):85-94. doi: 10.1093/aje/kwae135.
4
Prevention of Epithelial Ovarian Cancer.预防上皮性卵巢癌。
Cold Spring Harb Perspect Med. 2023 Aug 1;13(8):a038216. doi: 10.1101/cshperspect.a038216.
5
Immune Cell and Biochemical Biomarkers in Advanced Laryngeal Cancer.晚期喉癌中的免疫细胞和生化生物标志物
Dose Response. 2022 Jul 19;20(3):15593258221115537. doi: 10.1177/15593258221115537. eCollection 2022 Jul-Sep.
6
Prospective Analyses of Sedentary Behavior in Relation to Risk of Ovarian Cancer.久坐行为与卵巢癌风险关系的前瞻性分析
Am J Epidemiol. 2022 May 20;191(6):1021-1029. doi: 10.1093/aje/kwac018.
7
Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer.动态免疫/炎症精准医学:感染和癌症中的有益和有害炎症。
Front Immunol. 2021 Feb 23;12:595722. doi: 10.3389/fimmu.2021.595722. eCollection 2021.
8
Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer.卵巢癌蛋白质组分类器的定义及独立验证
Cancers (Basel). 2020 Sep 4;12(9):2519. doi: 10.3390/cancers12092519.
全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
4
Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors.血清 C 反应蛋白是大多数成人实体瘤中重要且强大的预后生物标志物。
PLoS One. 2018 Aug 23;13(8):e0202555. doi: 10.1371/journal.pone.0202555. eCollection 2018.
5
C-reactive protein and risk of ovarian cancer: A systematic review and meta-analysis.C反应蛋白与卵巢癌风险:一项系统评价与荟萃分析
Medicine (Baltimore). 2017 Aug;96(34):e7822. doi: 10.1097/MD.0000000000007822.
6
The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.术前C反应蛋白/白蛋白比值在卵巢癌中的预后价值
BMC Cancer. 2017 Apr 21;17(1):285. doi: 10.1186/s12885-017-3220-x.
7
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer.卵巢癌独特的分子与细胞微环境
Front Oncol. 2017 Feb 22;7:24. doi: 10.3389/fonc.2017.00024. eCollection 2017.
8
Inflammatory Markers of CRP, IL6, TNFα, and Soluble TNFR2 and the Risk of Ovarian Cancer: A Meta-analysis of Prospective Studies.CRP、IL6、TNFα和可溶性TNFR2的炎症标志物与卵巢癌风险:一项前瞻性研究的荟萃分析
Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1231-9. doi: 10.1158/1055-9965.EPI-16-0120. Epub 2016 Jun 8.
9
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.英国卵巢癌筛查协作试验(UKCTOCS)中的卵巢癌筛查与死亡率:一项随机对照试验
Lancet. 2016 Mar 5;387(10022):945-956. doi: 10.1016/S0140-6736(15)01224-6. Epub 2015 Dec 17.
10
Ovarian cancer: beyond resistance.卵巢癌:超越耐药性。
Nature. 2015 Nov 26;527(7579):S217. doi: 10.1038/527S217a.